Gelteq (GELS) Registration filing summary

Company overview and business model

• Focuses on developing and commercializing white label gel-based delivery solutions for prescription drugs, nutraceuticals, pet care, and other products, leveraging patent-pending multiple-ingredient dosage forms.

• Operates primarily through out-licensing technology and manufacturing existing products under license for third parties.

• Product suite spans five core verticals: pets, sports, pharmaceutical, over-the-counter, and nutraceutical, with a strategy to target markets with unmet needs such as dysphagia and pet health.

• Holds a portfolio of granted and pending patents across multiple jurisdictions, with ongoing R&D and partnerships with leading research institutions.

• Manufacturing is outsourced to large-scale facilities in China and the US, with quality control and regulatory compliance as key priorities.

Financial performance and metrics

• Reported net losses of AUD $3.5 million for both fiscal years ended June 30, 2024 and 2023, and a loss of AUD $3.3 million for the six months ended December 31, 2024.

• Revenue from contracts with customers was AUD $79,843 in FY2023, with no recognized revenue in FY2024 due to delayed customer payments; orders were shipped in FY2025.

• Cash and cash equivalents increased to AUD $3.0 million as of December 31, 2024, following the IPO and convertible note issuances.

• Accumulated losses totaled AUD $14.8 million as of December 31, 2024, with net assets of AUD $18.8 million.

• Ongoing negative operating cash flows, with working capital deficit reduced to AUD $1.3 million at December 31, 2024.

Use of proceeds and capital allocation

• May receive up to $12 million in gross proceeds from the sale of ordinary shares to Lincoln Park Capital Fund, to be used for research and development, marketing activities, and general working capital.

• Proceeds are intended to support global marketing, sales efforts, and further product development, with management retaining broad discretion over allocation.

• Additional capital may be required if sales targets are not met or for further growth opportunities.